Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies

URN to cite this document:: urn:nbn:de:bvb:355-epub-591506
DOI to cite this document:: 10.5283/epub.59150

Perl, Markus ; Herfeld, Konstantin ; Harrer, Dennis C.

; Höpting, Matthias ; Schweiger, Marina ; Sterz, Ulrich ; Knödler, Leonard ; Heimerl, Susanne ; Hansmann, Leo

; Herr, Wolfgang ; Poeck, Hendrik ; Wolff, Daniel

; Edinger, Matthias ; Hart, Christina ; Fante, Matthias Alexander

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(4MB)

Date of publication of this fulltext: 11 Sep 2024 10:09

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that has up to now been considered the result of disseminated intravascular coagulation (DIC) and liver dysfunction. We investigated the incidence and risk factors for hypofibrinogenemia in 41 consecutive adult ...